Empty Capsules Market Size, Share, Growth and Industry Analysis, By Types (Gelatin Capsules, Non-Gelatin Capsules), By Applications (Antibiotic and Antibacterial Drugs, Vitamins and Dietary Supplements, Antacid and Antiflatulent Preparations, Antianemic Preparations, Anti-inflammatory and Anti-rheumatic Drugs, Cardiac Therapy Drugs, Cough and Cold Preparations, Others Therapeutic Applications), Regional Insights and Forecast to 2035

Empty Capsules Market Size

The Global Empty Capsules Market was valued at USD 1,860.67 million in 2025 and is expected to reach USD 1,938.82 million in 2026, USD 2,020.25 million in 2027, and USD 2,807.67 million by 2035, expanding at a CAGR of 4.2% during the forecast period (2026–2035). The Empty Capsules Market is witnessing steady growth due to rising pharmaceutical manufacturing activities, increasing consumer demand for nutraceuticals, and the growing adoption of capsule-based drug delivery formats across healthcare sectors. Gelatin capsules continue to lead the market, accounting for nearly 70% of total revenue, supported by their widespread use in pharmaceutical formulations, while non-gelatin capsules represent approximately 30% of the market as demand for vegetarian and plant-based alternatives continues to rise. Based on application, antibiotics hold around 35% of overall demand, followed by dietary supplements at nearly 30%, reflecting the expanding focus on preventive healthcare and wellness products. In addition, anti-inflammatory and digestive health treatments contribute close to 20% of market consumption, highlighting the broad and growing role of empty capsules across pharmaceutical and nutraceutical applications worldwide. The increasing preference for convenient oral dosage forms and continuous innovation in capsule technologies are further supporting the long-term expansion of the Empty Capsules Market.

The US Empty Capsules Market demonstrates significant growth, driven by strong pharmaceutical and nutraceutical industries. More than 45% of capsule demand is from antibiotics and antibacterial drugs, while 25% comes from vitamins and dietary supplements. Around 35% of manufacturers in the US are shifting towards plant-based capsules, and over 20% of capsule sales are directed at preventive healthcare products, reinforcing the region’s leadership in advanced drug delivery systems.

Key Findings

• Market Size: Valued at $1860.67M in 2025, projected to touch $1938.82M in 2026 to $2807.67M by 2035 at a CAGR of 4.2%.
• Growth Drivers: Over 60% pharmaceutical demand, 35% nutraceutical adoption, and 25% preference for plant-based capsules fuel market expansion.
• Trends: 40% growth in vegetarian capsules, 30% fast-release capsule adoption, and 25% innovation in specialty dosage forms shape the market.
• Key Players: Capsugel, Suheung Co Ltd., Acg Worldwide, Qualicaps, Sunil Healthcare Limited & more.
• Regional Insights: Asia-Pacific 35% leads with nutraceutical demand, North America 30% driven by pharma, Europe 25% via supplements, Middle East & Africa 10% emerging.
• Challenges: 55% reliance on animal gelatin, 35% high compliance costs, and 20% supply chain instability limit growth.
• Industry Impact: 45% increased demand in drug delivery, 30% nutraceutical innovation, and 25% product diversification drive industry transformation.
• Recent Developments: 28% focus on vegetarian capsules, 25% specialty drug delivery, 22% eco-friendly innovations, and 15% digital capsule tech investments.

The Empty Capsules Market reflects a dynamic mix of pharmaceutical and nutraceutical growth, with more than 30% of new products targeting vegetarian capsules and 25% focusing on fast-release technologies. Increasing innovation in capsule coatings, coupled with 20% investment in eco-friendly production, strengthens the industry’s sustainability profile while enhancing product performance.

Empty Capsules Market Trends

The empty capsules market is witnessing robust growth driven by pharmaceutical and nutraceutical applications. Gelatin-based capsules account for nearly 70% of total usage, while vegetarian capsules represent 30% with increasing adoption due to plant-based demand. Over 55% of empty capsules are consumed in pharmaceutical drugs for antibiotics, vitamins, and anti-inflammatory medicines, while 25% are used in dietary supplements, and 20% in functional foods and personal health products. Hard gelatin capsules dominate with over 60% share compared to soft capsules holding 40%. Regionally, Asia-Pacific contributes over 40% of market share, followed by North America at 30%, Europe at 20%, and the Middle East & Africa at 10%.

Empty Capsules Market Dynamics

OPPORTUNITY

Rising nutraceutical adoption

Nutraceuticals contribute more than 35% of demand for empty capsules, fueled by growing health-conscious consumers. Vegetarian capsules show a 20% faster adoption rate compared to gelatin forms, supporting clean-label trends. More than 45% of supplement manufacturers are shifting towards plant-based capsule solutions.

DRIVERS

Expanding pharmaceutical applications

Over 60% of antibiotics and pain-relief drugs utilize empty capsules for oral delivery. Around 50% of global pharmaceutical companies prefer hard gelatin capsules for stability, while 25% are investing in advanced capsule technologies. Demand is further boosted by 30% rise in chronic disease treatments.

RESTRAINTS

"Fluctuating raw material supply"

Over 55% of empty capsules rely on animal-derived gelatin, making supply vulnerable to livestock-related fluctuations. Around 30% of manufacturers report increased dependency on alternative sources, while 20% face regulatory barriers in sourcing raw materials. Rising scrutiny on animal-based products impacts nearly 25% of global capsule producers.

CHALLENGE

"High manufacturing and compliance costs"

More than 40% of producers face cost escalation due to strict pharmaceutical-grade standards and GMP certifications. Approximately 35% of small-scale manufacturers struggle with compliance-related expenses, while 25% cite rising energy and processing costs. These challenges reduce scalability and restrict entry of nearly 20% of new market participants.

Segmentation Analysis

Global Empty Capsules Market size was USD 1860.67 Million in 2024 and is projected to touch USD 1938.82 Million in 2025 to USD 2807.68 Million by 2034, exhibiting a CAGR of 4.2% during the forecast period (2025–2034). By type, the market is divided into gelatin capsules and non-gelatin capsules, with each category showing distinct adoption rates, percentage distribution, and growth drivers across pharmaceutical and nutraceutical applications.

By Type

Gelatin Capsules

Gelatin capsules dominate the empty capsules market with wide pharmaceutical usage, particularly in antibiotics, pain relief, and vitamins. More than 70% of drug formulations prefer gelatin capsules due to affordability and stability, while 20% of dietary supplements also rely on this type. However, demand is gradually shifting towards alternatives due to rising plant-based preferences.

Gelatin Capsules held the largest share in the empty capsules market, accounting for USD 1357.17 Million in 2025, representing 70% of the total market. This segment is expected to grow at a CAGR of 3.8% from 2025 to 2034, driven by low cost, efficient drug delivery, and established pharmaceutical applications.

Top 3 Major Dominant Countries in the Gelatin Capsules Segment

• United States led the Gelatin Capsules segment with a market size of USD 407.15 Million in 2025, holding a 30% share and expected to grow at a CAGR of 3.5% due to strong pharmaceutical consumption and R&D.
• Germany held USD 271.43 Million in 2025, representing 20% share and projected to expand at a CAGR of 3.6% driven by healthcare innovations and supplement demand.
• China recorded USD 203.57 Million in 2025, with a 15% share and forecasted CAGR of 4.0% due to high medicine production and growing supplement industry.

Non-Gelatin Capsules

Non-gelatin capsules, often plant-based or made from HPMC, are increasingly favored by nutraceutical and vegan consumer groups. They account for 30% of global capsule demand, with over 45% of nutraceutical companies shifting to vegetarian options. Rising clean-label and allergen-free trends contribute significantly to the segment’s growth worldwide.

Non-Gelatin Capsules accounted for USD 581.65 Million in 2025, representing 30% of the total market. This segment is projected to grow at a CAGR of 5.0% from 2025 to 2034, supported by consumer preference for plant-based supplements, growing vegetarian population, and stricter dietary regulations in developed regions.

Top 3 Major Dominant Countries in the Non-Gelatin Capsules Segment

• India led the Non-Gelatin Capsules segment with a market size of USD 174.49 Million in 2025, holding a 30% share and expected to grow at a CAGR of 5.2% driven by large vegetarian population and expanding nutraceutical exports.
• Japan captured USD 116.33 Million in 2025, with a 20% share and projected CAGR of 5.1% owing to rising demand for premium dietary supplements.
• United Kingdom registered USD 87.25 Million in 2025, holding a 15% share and expected to grow at a CAGR of 5.3% fueled by clean-label supplement adoption and regulatory support for vegetarian products.

By Application

Antibiotic and Antibacterial Drugs

Antibiotic and antibacterial drugs dominate the application of empty capsules due to their effectiveness in oral delivery systems. More than 40% of prescriptions for bacterial infections prefer capsule-based dosage forms, with strong demand from hospitals and retail pharmacies worldwide.

Antibiotic and Antibacterial Drugs held the largest share, accounting for USD 678.59 Million in 2025, representing 35% of the total market. This segment is expected to grow at a CAGR of 4.0% from 2025 to 2034, driven by increasing bacterial infection cases, enhanced oral drug compliance, and stable drug formulation.

Top 3 Major Dominant Countries in the Antibiotic and Antibacterial Drugs Segment

• United States led with USD 203.58 Million in 2025, holding a 30% share and expected to grow at a CAGR of 3.9% due to high antibiotic prescription rates and pharmaceutical R&D.
• China recorded USD 135.72 Million in 2025, representing 20% share and projected to grow at a CAGR of 4.2% fueled by high infection prevalence and local drug manufacturing.
• India reached USD 101.79 Million in 2025, with a 15% share and CAGR of 4.4% supported by growing generics production and large patient population.

Vitamins and Dietary Supplements

Vitamins and dietary supplements contribute significantly to capsule consumption, accounting for more than 30% of global demand. Around 50% of supplement brands use vegetarian capsules to cater to health-conscious and vegan consumers, making this segment the fastest-growing in the nutraceutical sector.

Vitamins and Dietary Supplements accounted for USD 581.65 Million in 2025, representing 30% of the total market. This segment is expected to grow at a CAGR of 5.1% from 2025 to 2034, driven by lifestyle diseases, preventive healthcare trends, and increasing nutraceutical consumption.

Top 3 Major Dominant Countries in the Vitamins and Dietary Supplements Segment

• India led with USD 174.49 Million in 2025, holding a 30% share and expected CAGR of 5.3% due to rising nutraceutical exports and vegetarian population.
• United States held USD 145.41 Million in 2025, with a 25% share and CAGR of 5.0% due to high supplement consumption rates and premium wellness trends.
• Japan captured USD 116.33 Million in 2025, representing 20% share with CAGR of 5.2% driven by functional food demand and aging population needs.

Antacid and Antiflatulent Preparations

Antacid and antiflatulent preparations form a crucial application segment as over 25% of adults report regular usage for digestive health. Capsules offer faster absorption and better patient compliance, driving higher adoption in self-care products.

Antacid and Antiflatulent Preparations were valued at USD 145.41 Million in 2025, representing 7.5% of the market. This segment is expected to grow at a CAGR of 3.6% from 2025 to 2034, supported by digestive disorders, lifestyle factors, and expanding OTC capsule usage.

Top 3 Major Dominant Countries in the Antacid and Antiflatulent Preparations Segment

• United States led with USD 43.62 Million in 2025, holding a 30% share and CAGR of 3.5% due to high GERD prevalence and OTC adoption.
• Germany accounted for USD 29.08 Million in 2025, with 20% share and CAGR of 3.6% owing to rising digestive health awareness.
• China stood at USD 21.81 Million in 2025, holding 15% share with CAGR of 3.8% due to dietary habits and urban lifestyle changes.

Antianemic Preparations

Antianemic preparations utilize capsules for iron and vitamin B12 supplements, addressing anemia which affects nearly 25% of the global population. Women and children represent the highest consumer base in this segment.

Antianemic Preparations contributed USD 135.72 Million in 2025, representing 7% of the total market. This segment is expected to grow at a CAGR of 4.4% from 2025 to 2034, driven by nutritional deficiencies and rising health programs targeting anemia reduction.

Top 3 Major Dominant Countries in the Antianemic Preparations Segment

• India led with USD 40.72 Million in 2025, holding a 30% share and CAGR of 4.5% due to high anemia prevalence among women and children.
• Brazil captured USD 27.14 Million in 2025, with a 20% share and CAGR of 4.3% fueled by government healthcare programs.
• United States recorded USD 20.36 Million in 2025, holding 15% share and CAGR of 4.2% supported by nutritional supplement awareness.

Anti-inflammatory and Anti-rheumatic Drugs

Anti-inflammatory and anti-rheumatic drugs are widely delivered in capsule form, with over 20% of chronic pain management relying on capsule-based medications. Aging populations and arthritis prevalence are major factors driving this segment’s growth.

Anti-inflammatory and Anti-rheumatic Drugs reached USD 193.88 Million in 2025, representing 10% of the market. This segment is expected to grow at a CAGR of 4.0% from 2025 to 2034, driven by musculoskeletal conditions and elderly care demand.

Top 3 Major Dominant Countries in the Anti-inflammatory and Anti-rheumatic Drugs Segment

• United States led with USD 58.16 Million in 2025, holding a 30% share and CAGR of 4.1% due to arthritis prevalence and high healthcare spending.
• Germany recorded USD 38.78 Million in 2025, representing 20% share with CAGR of 4.0% fueled by aging demographics.
• Japan had USD 29.08 Million in 2025, holding 15% share and CAGR of 4.2% supported by elderly care drug adoption.

Cardiac Therapy Drugs

Cardiac therapy drugs account for a key capsule application as cardiovascular diseases remain among the top health concerns. More than 15% of heart-related therapies are delivered in capsule dosage forms, aiding patient adherence.

Cardiac Therapy Drugs accounted for USD 135.72 Million in 2025, representing 7% of the total market. This segment is projected to grow at a CAGR of 3.7% from 2025 to 2034, driven by heart disease prevalence and pharmaceutical innovation.

Top 3 Major Dominant Countries in the Cardiac Therapy Drugs Segment

• United States led with USD 40.72 Million in 2025, holding a 30% share and CAGR of 3.6% due to high cardiac cases and advanced treatment options.
• China captured USD 27.14 Million in 2025, with 20% share and CAGR of 3.8% driven by rising heart disease rates.
• United Kingdom recorded USD 20.36 Million in 2025, holding 15% share and CAGR of 3.7% owing to preventive healthcare initiatives.

Cough and Cold Preparations

Cough and cold preparations utilize capsules for quick relief, with seasonal flu and respiratory infections contributing significantly to capsule-based formulations. Around 10% of global capsule demand comes from this segment.

Cough and Cold Preparations were valued at USD 116.33 Million in 2025, representing 6% of the total market. This segment is forecasted to grow at a CAGR of 3.9% from 2025 to 2034, fueled by respiratory illnesses, seasonal demand, and OTC drug expansion.

Top 3 Major Dominant Countries in the Cough and Cold Preparations Segment

• United States led with USD 34.90 Million in 2025, holding a 30% share and CAGR of 3.8% due to high OTC sales.
• Canada recorded USD 23.27 Million in 2025, with 20% share and CAGR of 3.9% owing to winter flu patterns.
• Germany had USD 17.45 Million in 2025, holding 15% share and CAGR of 4.0% due to rising respiratory illnesses.

Others Therapeutic Applications

Other therapeutic applications include oncology, dermatology, and neurological treatments, contributing nearly 10% to the capsule market. These applications highlight the versatility and adaptability of capsule drug delivery systems in specialized therapies.

Others Therapeutic Applications accounted for USD 51.41 Million in 2025, representing 2.5% of the total market. This segment is projected to grow at a CAGR of 4.5% from 2025 to 2034, driven by specialized medicines, oncology treatments, and personalized healthcare trends.

Top 3 Major Dominant Countries in the Others Therapeutic Applications Segment

• Japan led with USD 15.42 Million in 2025, holding a 30% share and CAGR of 4.6% due to oncology advancements.
• United States recorded USD 10.28 Million in 2025, with 20% share and CAGR of 4.4% owing to neurological therapies.
• France captured USD 7.71 Million in 2025, representing 15% share and CAGR of 4.5% due to dermatology and oncology research.

Empty Capsules Market Regional Outlook

Global Empty Capsules Market size was USD 1860.67 Million in 2024 and is projected to touch USD 1938.82 Million in 2025 to USD 2807.68 Million by 2034, exhibiting a CAGR of 4.2% during the forecast period (2025–2034). Regionally, North America represents 30%, Europe 25%, Asia-Pacific 35%, and Middle East & Africa 10% of the market share.

North America

North America remains a strong market for empty capsules with extensive pharmaceutical and nutraceutical industries. More than 40% of capsules here are consumed in antibiotics and dietary supplements, with over 35% of demand coming from the United States alone. The region also shows growing adoption of vegetarian capsules.

North America held USD 581.65 Million in 2025, representing 30% of the global market. This segment is expected to grow at a CAGR of 4.0% from 2025 to 2034, driven by advanced pharmaceutical R&D, high supplement consumption, and increasing healthcare expenditure.

North America - Major Dominant Countries in the Empty Capsules Market

• United States led with USD 407.15 Million in 2025, holding a 70% share and CAGR of 4.1% due to strong drug consumption and healthcare infrastructure.
• Canada recorded USD 116.33 Million in 2025, representing 20% share and CAGR of 3.9% supported by dietary supplement growth.
• Mexico accounted for USD 58.17 Million in 2025, holding 10% share and CAGR of 4.0% driven by rising generics and low-cost drug manufacturing.

Europe

Europe shows a balanced mix of pharmaceutical innovation and nutraceutical adoption, with over 25% of capsule consumption attributed to dietary supplements. Around 30% of the region’s demand comes from Germany, France, and the UK collectively, reflecting strong consumer health awareness and government regulations supporting supplement growth.

Europe accounted for USD 484.71 Million in 2025, representing 25% of the total market. This segment is forecasted to grow at a CAGR of 3.9% from 2025 to 2034, driven by aging population, preventive health trends, and established pharmaceutical manufacturing bases.

Europe - Major Dominant Countries in the Empty Capsules Market

• Germany led with USD 145.41 Million in 2025, holding a 30% share and CAGR of 4.0% due to high supplement demand and pharmaceutical production.
• France registered USD 96.94 Million in 2025, representing 20% share and CAGR of 3.8% fueled by consumer preference for natural supplements.
• United Kingdom recorded USD 87.25 Million in 2025, with 18% share and CAGR of 4.1% owing to rising clean-label capsule demand.

Asia-Pacific

Asia-Pacific leads the empty capsules market with the largest share, accounting for 35% of global demand. More than 50% of growth is driven by China, India, and Japan. Rising nutraceutical consumption, expanding pharmaceutical production, and large populations contribute significantly to this region’s expansion.

Asia-Pacific accounted for USD 678.59 Million in 2025, representing 35% of the global market. This segment is expected to grow at a CAGR of 4.6% from 2025 to 2034, supported by dietary supplement adoption, healthcare access expansion, and export-oriented pharmaceutical manufacturing.

Asia-Pacific - Major Dominant Countries in the Empty Capsules Market

• China led with USD 237.51 Million in 2025, holding a 35% share and CAGR of 4.7% due to rising medicine manufacturing and local supplement demand.
• India captured USD 203.57 Million in 2025, representing 30% share and CAGR of 4.8% driven by generics production and large vegetarian population.
• Japan accounted for USD 135.72 Million in 2025, with a 20% share and CAGR of 4.5% fueled by aging population and functional food demand.

Middle East & Africa

Middle East & Africa represent an emerging market, contributing 10% of global capsule demand. Around 40% of demand comes from the Middle East due to expanding healthcare infrastructure, while 60% originates from Africa, where growing urbanization and improving access to medicines drive capsule consumption.

Middle East & Africa accounted for USD 193.88 Million in 2025, representing 10% of the global market. This segment is forecasted to grow at a CAGR of 3.7% from 2025 to 2034, driven by healthcare investments, rising generic drugs, and demand for affordable medicines.

Middle East & Africa - Major Dominant Countries in the Empty Capsules Market

• United Arab Emirates led with USD 58.16 Million in 2025, holding a 30% share and CAGR of 3.8% due to advanced healthcare infrastructure.
• South Africa recorded USD 38.78 Million in 2025, representing 20% share and CAGR of 3.7% fueled by increasing generic drug usage.
• Saudi Arabia accounted for USD 29.08 Million in 2025, holding 15% share and CAGR of 3.6% supported by rising supplement adoption.

List of Key Empty Capsules Market Companies Profiled

Investment Analysis and Opportunities in Empty Capsules Market

Investments in the empty capsules market are expanding as over 40% of funding is directed towards plant-based capsule innovations. Nearly 35% of investors are focusing on nutraceutical applications due to rising health-conscious populations. Around 25% of opportunities lie in expanding pharmaceutical dosage formulations, while 20% are linked to functional food and wellness sectors. More than 45% of regional investments are concentrated in Asia-Pacific, followed by 30% in North America, highlighting the demand potential across growing economies. Increasing preference for vegetarian capsules, which hold 30% of the market share, is drawing significant funding from both established and emerging manufacturers.

New Products Development

New product development in the empty capsules market is driven by innovation and customization. Over 30% of new launches focus on vegetarian capsules using HPMC or pullulan, while 25% target specialized capsules for probiotics and dietary supplements. About 20% of developments involve advanced capsule coatings improving drug stability, while 15% focus on fast-release capsules for enhanced absorption. More than 10% of R&D spending is allocated to allergen-free and clean-label capsule designs. Nearly 35% of pharmaceutical companies are collaborating with capsule manufacturers to co-develop innovative drug delivery systems, creating a strong pipeline of novel products to meet diverse healthcare needs.

Recent Developments

• Capsugel – Expansion of Plant-based Capsules: In 2024, Capsugel introduced a new line of vegetarian capsules, expanding its portfolio with more than 25% of products targeting clean-label consumers and 20% aimed at nutraceuticals.
• Acg Worldwide – Launch of Smart Capsule Technology: Acg unveiled smart capsules integrated with micro-sensors to track drug release, with 15% of trials showing improved patient compliance and 30% demonstrating higher absorption efficiency.
• Suheung Co Ltd. – Sustainability Initiatives: Suheung introduced eco-friendly capsule production methods, reducing energy use by 18% and water consumption by 22%, aligning 25% of their capacity with green manufacturing practices.
• Qualicaps – Expansion in Asia-Pacific: Qualicaps expanded its manufacturing base in Asia-Pacific, increasing production output by 28% and capturing 20% more regional share through partnerships with pharmaceutical and supplement companies.
• Sunil Healthcare Limited – Specialty Capsule Development: Sunil Healthcare launched acid-resistant capsules designed for probiotics, capturing 15% of demand in specialized nutraceuticals and 12% of demand from functional food manufacturers.

Report Coverage

The Empty Capsules Market report provides an in-depth analysis covering product types, applications, regional distribution, competitive landscape, and future opportunities. By type, gelatin capsules dominate with nearly 70% market share, while non-gelatin capsules account for 30%, showing faster adoption in nutraceuticals. By application, antibiotics and antibacterial drugs contribute around 35% of capsule use, vitamins and dietary supplements hold 30%, and the rest is spread across antacids, anti-inflammatory drugs, and other therapies. Regionally, Asia-Pacific leads with 35% of the market share, followed by North America at 30%, Europe at 25%, and Middle East & Africa at 10%. The report also covers investment insights, highlighting that more than 40% of funding is moving toward plant-based capsules, while 25% is concentrated in pharmaceutical applications. Key players, including Capsugel, Acg Worldwide, and Suheung Co Ltd., account for over 50% of the global share, with Capsugel leading at 28%. Emerging manufacturers contribute around 20% of the market with niche products. The study further outlines opportunities in vegetarian capsules, representing 30% of the demand, and emphasizes product innovation, with 30% of new developments focused on fast-release and allergen-free capsules. This comprehensive coverage enables stakeholders to identify growth avenues and competitive advantages across the supply chain.